We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Personalized Treatment Trial for Breast Cancer Launched
News

Personalized Treatment Trial for Breast Cancer Launched

Personalized Treatment Trial for Breast Cancer Launched
News

Personalized Treatment Trial for Breast Cancer Launched

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Personalized Treatment Trial for Breast Cancer Launched"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, has been launched to examine whether genes that are frequently associated with risk of recurrence for women with early-stage breast cancer can be used to assign patients to the most appropriate and effective treatment.

TAILORx is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and is coordinated by the Eastern Cooperative Oncology Group (ECOG).

All of the NCI-sponsored clinical trials groups that perform breast cancer research studies have collaborated in the trial's development and are participating in this study.

"This trial is important because it is one of the first to examine a methodology for personalizing cancer treatment," said NIH Director Elias A, Zerhouni, M.D.

The majority of women with early-stage breast cancer are advised to receive chemotherapy in addition to radiation and hormonal therapy, yet research has not demonstrated that chemotherapy benefits all of them equally.

TAILORx seeks to incorporate a molecular profiling test (a technique that examines many genes simultaneously) into clinical decision making, and thus spare women unnecessary treatment if chemotherapy is not likely to be of substantial benefit to them.

The study will enroll over 10,000 women at 900 sites in the United States and Canada.

Women recently diagnosed with estrogen receptor and/or progesterone receptor positive, Her2/neu negative breast cancer, which has not yet spread to the lymph nodes, are eligible for the study. Overexpression of the Her2/neu gene carries poorer prognosis for patients.

TAILORx will determine the most effective current approach to cancer treatment, with the fewest side effects, for women with early-stage breast cancer by using Oncotype DX ™, a validated diagnostic test developed by Genomic Health, Inc., Redwood City, Calif., in collaboration with the National Surgical Adjuvant Breast and Bowel Project (NSABP), a network of cancer research professionals.

Research appearing online in an issue of "Journal of Clinical Oncology" provides strong evidence for the value of using Oncotype DX™ to help women with this form of breast cancer determine whether they will benefit by adding chemotherapy to hormonal therapy.

This study, as well as several other similar studies in recent years, provided the basis for the launch of TAILORx.

"A large number of these women are receiving toxic chemotherapy unnecessarily, and we need a means of identifying them," said Jo Anne Zujeweski, M.D., senior investigator in the Clinical Investigation Branch of NCI's Cancer Therapy Evaluation Program.

"TAILORx could help change the way we treat breast cancer and improve the quality of patients' lives, helping to better identify women who are likely to benefit from chemotherapy from those who are not."

Oncotype DX™ measures the levels of expression of 21 genes (whether they are transcribed into messenger RNA) in breast tumors.

This assessment can estimate a person's risk of recurrence than standard characteristics, such as tumor size and grade.

Based on the Oncotype DX™ gene expression analysis, a recurrence score from 0 to 100 is generated; the higher the score, the greater a woman's chance of having a recurrence if treated with hormonal therapy alone.

Women will be studied for 10 years, with an additional follow-up of up to 20 years after initial therapies. Based on their recurrence score, women will be assigned to three different treatment groups in the TAILORx study:

- Women with a recurrence score higher than 25 will receive chemotherapy plus hormonal therapy (the standard of care)

- Women with a recurrence score lower than 11 will receive hormonal therapy alone

- Women with a recurrence score of 11 to 25 will be randomly assigned to receive adjuvant hormonal therapy, with or without chemotherapy.

TAILORx is designed primarily to evaluate the effect of chemotherapy on those with a recurrence score of 11 to 25.

Women in this last group will comprise 4,390 women, or about 44 percent of the study population.

Because the degree of benefit of chemotherapy for women with recurrence scores between 11 and 25 is uncertain, TAILORx seeks to determine if the Oncotype DX™ test will be helpful in future treatment planning for this group.

Hormonal therapies in the trial are assigned based on menopausal status and include tamoxifen and the aromatase inhibitors anastrozole, letrozole and exemestane.

Women on the chemotherapy arm of the trial will receive one of several standard combination chemotherapy regimens considered to be the best available standard care.

It will also be possible for women participating in TAILORx to participate in other NCI-sponsored clinical trials, provided the therapy prescribed in the clinical trial is consistent with their assigned therapy in TAILORx.

"With TAILORx, we are taking a big step toward personalized medicine. By using cutting- edge diagnostic tests, we'll be able to customize an individual's cancer treatment," said Joseph Sparano, M.D., Montefiore Medical Center, Bronx, NY, and Eastern Cooperative Oncology Group protocol chair.

Advertisement